Blood cancers

Sustained disease control with continuous lenalidomide in MM

Patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) have better overall survival and progression free survival with continuous lenalidomide and low-dose dexamethasone compared to fixed duration front line regimens, real-world data shows. The retrospective trial compared the outcomes of NDMM patients within the UK Thames Valley Cancer Network who received one cycle of fixed duration ...

Already a member?

Login to keep reading.

© 2021 the limbic